2012-10-04 17:35:52 - New Pharmaceuticals market report from Global Markets Direct: "Diarrhea - Pipeline Review, H2 2012"

Global Markets Direct's, 'Diarrhea - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Diarrhea, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diarrhea. Diarrhea - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.


Full Report Details at
- www.fastmr.com/prod/468368_diarrhea_pipeline_review_h2_2012.aspx


Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for

the indicated disease.

Scope

* A snapshot of the global therapeutic scenario for Diarrhea.
* A review of the Diarrhea products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Diarrhea pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for Diarrhea.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Diarrhea pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Diarrhea Overview
Therapeutics Development
An Overview of Pipeline Products for Diarrhea
Diarrhea Therapeutics under Development by Companies
Diarrhea Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Diarrhea Therapeutics - Products under Development by Companies
Diarrhea Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Diarrhea Therapeutics Development
Cubist Pharmaceuticals, Inc.
ViroPharma Incorporated
Optimer Pharmaceuticals, Inc.
Menarini Group
Shire Plc
Cosmo Pharmaceuticals S.p.A
Lexicon Pharmaceuticals, Inc.
Thallion Pharmaceuticals Inc.
Creative Antibiotics Sweden AB
Mucosis B.V.
Helsinn Healthcare S.A.
Ventria Bioscience
Osel Inc.
Tranzyme Pharma, Inc.
Tioga Pharmaceuticals, Inc.
Napo Pharmaceuticals, Inc.
Antibe Therapeutics, Inc.
Dr. Falk Pharma GmbH
Eurofarma
Diarrhea - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ibodutant - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CB-183,315 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
crofelemer - Drug Profile
Product Description
Mechanism of Action
R&D Progress
crofelemer - Drug Profile
Product Description
Mechanism of Action
R&D Progress
crofelemer - Drug Profile
Product Description
Mechanism of Action
R&D Progress
mesalamine granules - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TZP-201 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
asimadoline - Drug Profile
Product Description
Mechanism of Action
R&D Progress
asimadoline - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rifamycin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
fidaxomicin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ACAM-Cdiff - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ZP-1846 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ACE-527 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CFTR Inhibitors - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lactobacillus Reuteri - Drug Profile
Product Description
Mechanism of Action
R&D Progress
lanreotide acetate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rifaximin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
WRSS-1 Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=468368&dt=t

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.